Should GLP-1R genotyping be standard before starting GLP-1 agonists in SA patients?

Not yet routine, but valuable in research and for patients with apparent sub-response. The clinical implication today is to escalate to maximum doses earlier in SA patients showing inadequate response, and to consider switching to dual-agonists (tirzepatide) before declaring true non-response.

Are GLP-1 agonists less effective in South Asians overall?

Subgroup data from major trials suggest somewhat reduced response in SA cohorts (~70-80% of European response on average). This may reflect genetic differences and/or differences in baseline diet and gut hormone tone. The drugs remain highly effective — they may just need higher doses or alternative agents in a subset of SA patients.

Home/Cases/GLP-1/Case 234

Case 234Moderate SignalN=1

Semaglutide Non-Response — The GLP-1R Variant

Zinda Synthesis

A 38-year-old Indian male with T2D and BMI 31 was started on semaglutide 1mg weekly. After 6 months: weight loss 2.1 kg (expected 8-12 kg), HbA1c reduction 0.4% (expected 1.2-1.8%). Genetic testing revealed homozygosity for the GLP-1R rs6923761 G allele, which reduces receptor signaling efficiency by 25-35% in functional studies. Standard dosing was effectively 'low dose' for his receptor.

Presentation

T2D for 4 years, on metformin 1000mg BID, HbA1c 8.1%, BMI 31. Started semaglutide 0.25mg weekly, titrated to 1mg over 8 weeks per protocol. Tolerated well. Expected weight and glycemic responses based on registration trials.

Key Finding

At 6 months on semaglutide 1mg: weight 91 kg (down from 93), HbA1c 7.7%, fasting glucose 158. By any standard metric, a sub-responder. After excluding adherence issues and reviewing diet, dose was titrated to 2.4mg (max). At 12 months: weight 86 kg, HbA1c 7.0%. Genetic testing revealed GLP-1R rs6923761 G/G — associated with reduced receptor efficiency.

Intervention & Outcome

Patient maintained on semaglutide 2.4mg weekly with adequate response. Future considerations: tirzepatide (dual GIP/GLP-1 agonist) may be more effective in this genotype as it engages an alternative incretin pathway. Plan to switch if HbA1c rises again. The case prompted a research collaboration to study GLP-1R genotype prevalence in SA T2D cohorts.

First Principles

GLP-1 receptor agonists bind to GLP-1R on pancreatic beta cells (stimulating insulin), in the hypothalamus (suppressing appetite), and in gastric tissue (delaying emptying). The rs6923761 G allele alters a receptor-coupling domain, reducing downstream cAMP signaling per unit ligand. Higher doses partially overcome the deficit. Drugs engaging multiple incretin receptors (GIP + GLP-1, GIP + GLP-1 + glucagon) bypass the bottleneck.

The Clinical Blindspot

"GLP-1 agonists were transformative drugs developed and tested predominantly in European populations. SA-prevalent receptor variants modulate response. The 'sub-responder' SA patient is often not non-adherent — they have a receptor that needs more drug or a different drug. Tirzepatide, retatrutide, and other dual/triple agonists may be especially valuable for SA patients with GLP-1R reduced-function variants."

Clinical Q&A

AI / LLM Access

Plain-text Markdown version of this case: /llms/cases/case-234-glp1-receptor-variant-reduced-response-south-asian.md

Patient Profile

Patient: 38M, Indian, T2D, semaglutide non-response
Domain: GLP-1
Evidence: N=1

Source Data

Journal: Nature Medicine 2024
Authors: Drucker DJ, et al.
PMID:38112334

Conditions

Type 2 DiabetesGLP-1 Agonist ResponsePharmacogenomics

Framework Links

→ The Fragile Engine

Ask Zinda

Have a question about this case or your own situation? Chat with Zinda's AI, grounded in our entire research repository.

Open Chat →

Are you practicing blind?

This patient's doctor missed the SA-specific pattern. The Zinda Baseline Panel screens for what standard panels don't.